Streetbeat News

Revenues

BRKR

Bruker Corporation (BRKR) announced preliminary Q4 2023 revenue expectations to exceed $830M, surpassing the $793.24M estimate. Full-year 2023 revenue is also expected to top $2.94B, against a $2.90B estimate. The company anticipates over 12% organic growth for Q4 and over 13% for the full year. Additionally, Bruker provided a positive preliminary outlook for 2024, expecting solid organic growth and non-GAAP EPS improvement. However, these figures are not yet finalized or audited, and the actual results may differ.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:18 pm

NWL

Newell Brands Inc (NWL) is undergoing an organizational realignment to enhance commercial capabilities, which includes cutting office roles by 7% by the end of 2024. The company aims to optimize its real estate footprint and implement cost-reduction initiatives. These changes are part of the 'Where to Play / How to Win' strategy introduced in June 2023. Expected annualized pre-tax savings are $65 million to $90 million, with restructuring charges of $75 million to $90 million. NWL's stock rose 2.68% to $8.64.

Portfolio Pulse from Shivani Kumaresan

January 08, 2024 | 5:14 pm

VRSK

Five analysts have recently updated their ratings on Verisk Analytics (NASDAQ:VRSK), with an average 12-month price target of $262.6, reflecting a slight increase from the previous target. The company is a leading provider of data analytics for the U.S. insurance industry and has shown strong financial performance with significant revenue growth, high net margin, and ROE. However, it has a high debt-to-equity ratio. Analysts' actions include both upgrades and downgrades, with price targets ranging from $253.00 to $285.00.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 5:01 pm

MKL

Analysts have provided mixed reviews on Markel Group (NYSE:MKL) with a range of ratings from 'Sell' to 'Hold'. The average 12-month price target is now $1393.75, down from $1600.00, indicating a 12.89% decrease. Markel's business includes specialty insurance and reinsurance, with recent revenue growth of 7.38% but below-average net margin and ROE. The company's debt-to-equity ratio is healthy at 0.28.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 5:00 pm

NTAP

Over the past three months, 10 analysts have provided diverse ratings for NetApp (NASDAQ:NTAP), with a recent shift towards a somewhat bearish stance in the last 30 days. The average 12-month price target for NTAP has been raised to $87.4, indicating a 12.05% increase from the previous target of $78.00. Analysts from firms like JP Morgan, Citigroup, and Morgan Stanley have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. NetApp's financial indicators show a market capitalization below industry benchmarks, a revenue decline of -6.07% over 3 months, but strong profitability with a net margin of 14.92%, an ROE of 28.36%, and an ROA of 2.54%. However, the company's debt-to-equity ratio of 3.46 suggests a higher level of debt.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 5:00 pm

TKR

Analysts have provided mixed ratings for Timken (NYSE:TKR) with an average 12-month price target of $82.67, down from $97.00. Recent actions include lowered price targets by analysts from Morgan Stanley, Jefferies, Stifel, Keybanc, Citigroup, and B of A Securities. Timken's financials show a revenue growth rate of 0.55% as of September 30, 2023, but lag in net margin, ROE, ROA, and face high debt-to-equity ratio challenges.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 5:00 pm

BCRX

BioCryst Pharmaceuticals (BCRX) shares are up following the company's preliminary Q4 revenue guidance, which exceeded expectations. Additionally, BioCryst anticipates achieving positive EPS and cash flow in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:55 pm

ANF

Abercrombie & Fitch Co (NYSE:ANF) shares surged after the company updated its Q4 and FY2023 guidance, raising net sales and operating margin outlooks. Q4 net sales are now expected to grow in the high-teens, with an operating margin of around 15%, up from the previous 12%-14% range. FY23 net sales outlook increased to 14%-15% growth from 12%-14%, and operating margin is anticipated to be around 11%, up from 10%. CEO Fran Horowitz attributed the positive adjustment to strong customer response to product assortments and marketing. The company believes these results will exceed the Always Forward Plan 2025 financial targets ahead of schedule. ANF shares rose by 7.77% to $97.57.

Portfolio Pulse from Shivani Kumaresan

January 08, 2024 | 4:54 pm

BA

DADA

DTC

PACB

SPR

Boeing shares fell 6.6% after an exit door blew out of a 737 aircraft, leading to the FAA grounding 171 jets. Other stocks also moved lower: Dada Nexus dropped 38.1% due to suspicious practices in revenue reporting; Solo Brands decreased 34.7% after cutting revenue guidance; Prothena fell 25.1% after program updates; Pacific Biosciences declined 15.1% with preliminary FY23 revenue announcement; and Spirit AeroSystems dropped 6.5% as it was involved with the faulty door on the Boeing aircraft.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 4:46 pm

ARDX

Ardelyx shares have seen an uptick following the company's positive update on its 2023 progress and its optimistic outlook for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:05 pm